-
PacBio launches HiFiViral SARS-CoV-2 kit and enhanced microbial whole-genome sequencing
Time of Update: 2022-01-05
The powerful SARS-CoV-2 sequencing kit and upgraded microbial whole-genome assembly workflow enable public health laboratories to expand pathogen surveillance programsPacBio announced the launch of the HiFiViral SARS-CoV-2 kit .
-
Monitoring individual triggers can reduce atrial fibrillation episodes
Time of Update: 2022-01-05
Research results include:Patients who completed the individualized trigger study reported a lower frequency of atrial fibrillation episodes within four weeks after the test than those who tracked only AFib episodes .
-
Large-scale studies have shown that electroconvulsive therapy is safe for the treatment of mental illness
Time of Update: 2022-01-04
Professor G?ran Hajak, the corresponding author from the Bamberg Social Foundation in Germany, said: "Our research provides evidence that people's negative attitudes towards electroconvulsive therapy (one of the most effective methods for the treatment of mental illness) urgently need to be corrected .
-
Genting Sunshine is included in the MSCI China Small Cap Index
Time of Update: 2022-01-04
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
HK), a biopharmaceutical company focusing on the development and commercialization of innovative drugs, is committed to satisfying the unsatisfied Asian market For medical needs, it was announced today that the company was included in the MSCI China Small Cap Index.
-
Suffer from psoriasis?
Time of Update: 2022-01-04
. "Now, Croft and his team at LJI's Autoimmune and Inflammation Center have discovered how a key protein called TWEAK destroys the skin cells of patients with psoriasis .
-
Build a strategic resource platform to help the trillion-level life and health industry develop Wuhan's national-level human genetic resource bank was officially put into use
Time of Update: 2022-01-04
" Deng Zixin, academician of the Chinese Academy of Sciences and dean of the Wuhan Institute of Biotechnology, introduced that the Wuhan sample bank will be established Innovative service mechanism, create a personalized, flexible, standardized, and shared resource pool, connect upstream and downstream basic, clinical, and industrial development needs, adhere to the strategic goal of "domestic first, international first-class", and become a third-party human genetics Benchmarking and demonstration of the resource library .
-
Chaintech's new crown paper won the Shenzhen First Outstanding Natural Science Academic Paper Award
Time of Update: 2022-01-04
Temperature dependence of the SARS-CoV-2 affinity to human ACE2 determines COVID-19 progression and clinical outcome" won the 2021 Shenzhen Science and Technology Association Outstanding Natural Science Academic Paper Award .
-
Shanghai Hutchison Pharmaceutical was awarded "National Technology Innovation Demonstration Enterprise"
Time of Update: 2022-01-04
62em; font-family:"Arial"; color:black; margin:0in; } </> Shanghai, November 24, 2021 /PRNewswire/ - On November 19, the Ministry of Industry and Information Technology announced the list of 2021 "National Technological Innovation Demonstration Enterprises", a total of 58 companies, only 2 in Shanghai, and Shanghai Hutchison Pharmaceuticals Listed among them .
-
Corning Jerry KN046 combined with chemotherapy for the treatment of advanced pancreatic cancer phase III registration clinical trial application was approved by CDE
Time of Update: 2022-01-04
HK) announced that the PD-L1/CTLA-4 bispecific antibody KN046 combined with albumin paclitaxel and gemcitabine for the treatment of advanced stages The Phase III registration clinical study (KN046-303) application for pancreatic cancer was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration .
-
BeiGene completes the acquisition of land for U.S. production bases and clinical R&D centers
Time of Update: 2022-01-04
The company announced today that it has completed the acquisition of land in the Princeton West Innovation Park in Hopewell, New Jersey, for the construction of a new 42-acre (approximately 170,000 square meters) production base and clinical research and development center .
-
BeiGene initiates the first human clinical trial of the TYK2 inhibitor BGB-23339 under development
Time of Update: 2022-01-04
prntblns{ BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt } Beijing, China and Cambridge, Massachusetts, November 22, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) is a science-based global biotechnology company , Focusing on the development of innovative and affordable drugs .
-
BeiGene announced that Baiyueze (R) (Zebutinib) was approved in the EU for the treatment of adult Fahrenheit macroglobulinemia
Time of Update: 2022-01-04
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prn
-
Huante Biotech brings zebrafish biotechnology to InnoCosme 2021
Time of Update: 2022-01-04
Zebrafish technology helps research and development of the efficacy of bird's nest acidOn the afternoon of November 18th, Xiang Wei, technical manager of Wuhan Zhongke Optics Valley Green Biotechnology Co.
-
"Compilation of talents to create the future", 2021 Boehringer Ingelheim Innovation Competition ended perfectly
Time of Update: 2022-01-04
62em; font-family:"Arial"; color:black; margin:0in; } </>Shanghai, November 23, 2021/PRNewswire/ - The 2021 "Innovation Competition" finals hosted by the world's leading biopharmaceutical company Boehringer Ingelheim successfully concluded at the ATLATL Darts Accelerator in Zhangjiang Science City, Shanghai .
-
Preface Zhenda Li Yuan: Entering Sequoia China Smart Medical Genomics Incubator (driven by Meena technology), opening a new stage of multi-omics industry collaboration
Time of Update: 2022-01-04
Xu Zhenda General Manager Li Yuan"Based on the model created by this project, we hope to provide a high-quality data platform that links the upstream and downstream of the industry chain and promotes the research and development of innovative drugs .
-
Global COVID-19 security innovation company expands products
Time of Update: 2022-01-04
S. Occupational Safety and Health Administration Coronavirus Disease RulesBoston, November 24, 2021/PRNewswire/ - Safely2Prosperity LLC CEO, JD, MBA John Norris announced the launch of a new S2P "COVID-19 Security Platform" and "Employee Dashboard" to achieve Quick demonstration and immediate deployment .
-
CStone Pharmaceuticals and Hengrui Pharmaceuticals reached a strategic cooperation and exclusive license agreement for CS1002 (anti-CTLA-4 monoclonal antibody) in the Greater China region
Time of Update: 2022-01-04
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prn
-
Twist Bioscience establishes a new company Revealar Biotherapeutics to develop and commercialize antibody therapies for COVID-19 and other refractory diseases
Time of Update: 2022-01-04
The new company will develop and commercialize an antibody discovered and optimized by Twist Biopharma (a division of Twist Bioscience) that neutralizes all known variants of the SARS-CoV-2 virus in preclinical studies .
-
Following the "China Association for Science and Technology Development Plan", 2022 Nanjing Scientific Instruments and Laboratory Equipment Exhibition Yang Fan set sail
Time of Update: 2022-01-04
The exhibition organizing committee keeps abreast of current affairs and follows the "China Association for Science and Technology Development Plan" to put scientific and technological innovation and scientific popularization in the first place, with the goal of building a highly standardized exhibition platform .
-
Keji Pharmaceutical's independent research and development of CAR-T product CT041 was approved for Canadian clinical trial
Time of Update: 2022-01-04
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
HK), an innovative CAR-T cell therapy company focused on the treatment of hematological malignancies and solid tumors, announced today, The company's self-developed CT041, an autologous CAR-T candidate for CLDN 18.
